Abstract
BackgroundMeningiomas are the most common benign intracranial tumors. However, even WHO grade I meningiomas occasionally show local tumor recurrence. Prognostic factors for meningiomas have not been fully established. Neutrophil-to-lymphocyte ratio (NLR) has been reported as a prognostic factor for several solid tumors. The prognostic value of NLR in meningiomas has been analyzed in few studies.Materials and MethodsThis retrospective study included 160 patients who underwent surgery for meningiomas between October 2010 and September 2017. We analyzed the associations between patients’ clinical data (sex, age, primary/recurrent, WHO grade, extent of removal, tumor location, peritumoral brain edema, and preoperative laboratory data) and clinical outcomes, including recurrence and progression-free survival (PFS).ResultsForty-four meningiomas recurred within the follow-up period of 3.8 years. WHO grade II, III, subtotal removal, history of recurrence, Ki-67 labeling index ≥3.0, and preoperative NLR value ≥2.6 were significantly associated with shorter PFS (P < 0.001, < 0.001, 0.002, < 0.001, and 0.015, respectively). Furthermore, NLR ≥ 2.6 was also significantly associated with shorter PFS in a subgroup analysis of WHO grade I meningiomas (P = 0.003). In univariate and multivariate analyses, NLR ≥2.6 remained as a significant predictive factor for shorter PFS in patients with meningioma (P = 0.014).ConclusionsNLR may be a cost-effective and novel preoperatively usable biomarker in patients with meningiomas.
Highlights
Meningioma is the most common primary brain tumor, accounting for 37.6% of all brain tumors [1]
Forty-four meningiomas recurred within the follow-up period of 3.8 years
WHO grade II, III, subtotal removal, history of recurrence, Ki-67 labeling index ≥3.0, and preoperative Neutrophil-to-lymphocyte ratio (NLR) value ≥2.6 were significantly associated with shorter progression-free survival (PFS) (P < 0.001, < 0.001, 0.002, < 0.001, and 0.015, respectively)
Summary
Meningioma is the most common primary brain tumor, accounting for 37.6% of all brain tumors [1]. Even benign WHO grade I meningiomas occasionally show rapid growth and may recur after total removal [2]. Various prognostic factors for meningiomas have been described in previous studies, and among those factors, the most reliable clinical factors have been WHO grade and the extent of removal (EOR) [3, 4]. Other studies have not shown a significant correlation between Ki-67 LI and poor prognosis [8, 9]. These factors are based on postoperative information; no preoperative prognostic factors have been established. Even WHO grade I meningiomas occasionally show local tumor recurrence. Prognostic factors for meningiomas have not been fully established. The prognostic value of NLR in meningiomas has been analyzed in few studies
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
